Showing 1 - 10 of 12 Maen Abdelrahim
M3541 in Combination With Radiotherapy in Subjects With Solid Tumors

Status: Open Not Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Michelle Guthrie

Phone: 713.441.6564

This dose-escalation study will evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic, and explore antitumor activity of M3541 in combination with fractionated palliative radiotherapy (RT) in subjects with solid tumors with ma ... Read more >

A Phase 2, Multicenter, Open-label, Safety and Efficacy Study of XERMELO® (Telotristat Ethyl) Plus First-line Chemotherapy in Patients With Locally Advanced, Unresectable, Recurrent or Metastatic Biliary Tract Cancer (BTC)

Status: Open Not Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Meena Medepalli

Phone: 713.441.4203

A Phase 2, multicenter, open-label, 2-stage study to assess the safety, tolerability, and efficacy of XERMELO in combination with first-line (1L) therapy (cisplatin [cis] plus gemcitabine [gem]) in patients with unresectable, locally advanced, r ... Read more >

A Study of Zolbetuximab Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Denesha Potts

Phone: 713.441.6011

The purpose of this study is to evaluate the efficacy of zolbetuximab plus capecitabine and oxaliplatin (CAPOX) compared with placebo plus CAPOX (as first-line treatment) as measured by Progression Free Survival (PFS). This study will also ev ... Read more >

A Study to Assess the Antitumor Activity and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Jose Cruz

Phone: 713.441.4457

The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall survival and assess the safety and tolerability of the combination treatment. This study will also ... Read more >

A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Jose Cruz

Phone: 713.441.4457

The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement. < ... Read more >

A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)

Status: Open Not Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Denesha Potts

Phone: 713.441.6011

The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement. < ... Read more >

ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Michelle Guthrie

Phone: 713.441.6564

Open label, multi-center dose escalation and dose expansion study designed to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor effects of ALRN-6924 in patients with advanced solid tumors or lymphomas with wild-typ ... Read more >

CDX-1140 : A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Michelle Guthrie

Phone: 713.441.6564

This is a study to determine the maximum tolerated dose (MTD) for CDX-1140, either alone or in combination with CDX-301, and to further evaluate its tolerability and efficacy in expansion cohorts once the MTD is determined. ... Read more >

Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Jose Cruz

Phone: 713.441.4457

This randomized phase III trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA) mismatch repair colorectal cancer that has spread to other places in ... Read more >

N1048 Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery

Status: Open Not Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Denesha Potts

Phone: 713.441.6011

PURPOSE: This randomized phase II/III trial studies how well chemotherapy alone compared to chemotherapy plus radiation therapy works in treating patients with rectal cancer undergoing surgery. ... Read more >

Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Jose Cruz

Phone: 713.441.4457

The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) in combination with gemcitabine and nab-paclitaxel, for front line treatment of locally-advanced pancreat ... Read more >

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Michelle Guthrie

Phone: 713.441.6564

RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and ... Read more >

Live Chat Available